[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-GANX":3,"homepage-market-summary":31,"stock-news-GANX":172},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"GANX","2026-10-02",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Gain Therapeutics, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.","21","Bethesda, MD",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},1.71,1.75,1.78,1.7,1.72,-0.01,-0.58,381168.611983,1668,1.7346,4.34,1.53,908493.258405484,6.4,1395,{"status":32,"indices":33,"watchlist":77,"sectors":99,"benchmarks":154},"success",[34,42,49,56,63,70],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":40,"sparkline":41,"date":5},"SPX","S&P 500",7722.72,56.27,0.73,true,"0.0,5.0 2.3,8.0 4.6,10.4 6.9,13.4 9.3,9.1 11.6,11.5 13.9,13.8 16.2,16.0 18.5,10.3 20.8,9.5 23.2,2.0 25.5,2.0 27.8,5.9 30.1,6.0 32.4,3.4 34.7,7.3 37.1,8.2 39.4,9.4 41.7,8.5 44.0,4.8",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":40,"sparkline":48,"date":5},"NDX","NASDAQ 100",30807.93,306.37,1,"0.0,11.5 2.3,11.7 4.6,12.4 6.9,14.8 9.3,12.8 11.6,14.6 13.9,16.0 16.2,15.9 18.5,12.2 20.8,10.7 23.2,4.4 25.5,2.6 27.8,4.5 30.1,4.5 32.4,3.5 34.7,6.0 37.1,5.5 39.4,5.0 41.7,4.3 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":40,"sparkline":55,"date":5},"DJI","DOW JONES",51177,250,0.49,"0.0,2.0 2.3,5.5 4.6,7.8 6.9,9.5 9.3,6.7 11.6,7.5 13.9,9.4 16.2,12.9 18.5,11.1 20.8,11.7 23.2,9.6 25.5,10.7 27.8,12.6 30.1,13.5 32.4,10.8 34.7,12.8 37.1,13.5 39.4,16.0 41.7,15.9 44.0,14.5",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":40,"sparkline":62,"date":5},"COMP","NASDAQ Composite",27190.86,319.27,1.19,"0.0,10.2 2.3,11.1 4.6,13.0 6.9,14.9 9.3,12.1 11.6,13.7 13.9,16.0 16.2,16.0 18.5,11.1 20.8,10.0 23.2,3.4 25.5,2.0 27.8,5.4 30.1,5.4 32.4,3.9 34.7,6.7 37.1,6.9 39.4,6.2 41.7,6.1 44.0,2.6",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":68,"is_up":40,"sparkline":69,"date":5},"RUT","RUSSELL 2000",2815.2,25,0.9,"0.0,2.0 2.3,3.0 4.6,6.1 6.9,8.4 9.3,7.5 11.6,8.8 13.9,10.4 16.2,11.3 18.5,10.2 20.8,11.2 23.2,10.1 25.5,8.8 27.8,12.9 30.1,13.1 32.4,12.8 34.7,14.4 37.1,15.1 39.4,16.0 41.7,15.1 44.0,13.2",{"symbol":71,"name":72,"price":73,"change":74,"pct_change":75,"is_up":14,"sparkline":76,"date":5},"VIX","CBOE VIX",15.31,-1.08,-6.59,"0.0,14.8 2.3,10.2 4.6,7.3 6.9,2.0 9.3,9.7 11.6,4.9 13.9,4.5 16.2,2.5 18.5,11.3 20.8,13.7 23.2,13.5 25.5,16.0 27.8,12.3 30.1,10.4 32.4,13.5 34.7,8.8 37.1,8.9 39.4,7.8 41.7,7.6 44.0,11.8",[78,85,92],{"symbol":79,"name":80,"price":81,"change":82,"pct_change":83,"is_up":40,"sparkline":84,"date":5},"NVDA","NVIDIA Corp",233.95,3.09,1.34,"0.0,16.0 7.3,15.3 14.7,9.6 22.0,12.1 29.3,10.3 36.7,6.6 44.0,2.0",{"symbol":86,"name":87,"price":88,"change":89,"pct_change":90,"is_up":40,"sparkline":91,"date":5},"AAPL","Apple Inc",333.69,3.37,1.02,"0.0,8.2 7.3,2.0 14.7,5.2 22.0,16.0 29.3,11.7 36.7,14.9 44.0,10.9",{"symbol":93,"name":94,"price":95,"change":96,"pct_change":97,"is_up":40,"sparkline":98,"date":5},"TSLA","Tesla Inc",370.59,16.48,4.65,"0.0,2.0 7.3,5.3 14.7,13.4 22.0,16.0 29.3,14.9 36.7,15.3 44.0,6.1",[100,105,110,114,119,124,129,134,139,144,149],{"name":101,"etf":102,"change":103,"price":104,"is_up":40},"Technology","XLK",1.01,199.81,{"name":106,"etf":107,"change":108,"price":109,"is_up":40},"Financials","XLF",0.06,53.49,{"name":111,"etf":112,"change":21,"price":113,"is_up":14},"Healthcare","XLV",166.18,{"name":115,"etf":116,"change":117,"price":118,"is_up":40},"Consumer Cycl","XLY",1.13,110.04,{"name":120,"etf":121,"change":122,"price":123,"is_up":40},"Consumer Staples","XLP",0.25,80.53,{"name":125,"etf":126,"change":127,"price":128,"is_up":40},"Energy","XLE",0.4,62.95,{"name":130,"etf":131,"change":132,"price":133,"is_up":40},"Industrials","XLI",0.78,169.95,{"name":135,"etf":136,"change":137,"price":138,"is_up":40},"Materials","XLB",0.66,48.86,{"name":140,"etf":141,"change":142,"price":143,"is_up":40},"Real Estate","XLRE",0.32,40.81,{"name":145,"etf":146,"change":147,"price":148,"is_up":40},"Utilities","XLU",0.38,39.83,{"name":150,"etf":151,"change":152,"price":153,"is_up":40},"Comm Services","XLC",0.35,110.32,[155,160,164,168],{"ticker":156,"name":157,"price":158,"change":159,"is_up":40},"SPY","SPDR S&P 500 ETF",769.64,0.74,{"ticker":161,"name":162,"price":163,"change":90,"is_up":40},"QQQ","Invesco QQQ Trust",749.58,{"ticker":165,"name":166,"price":167,"change":54,"is_up":40},"DIA","SPDR Dow Jones ETF",511.1,{"ticker":169,"name":170,"price":171,"change":68,"is_up":40},"IWM","iShares Russell 2000",281.52,{"ticker":4,"count":173,"articles":174},7,[175,181,187,193,199,205,211],{"title":176,"link":177,"pubDate":178,"description":179,"source":180},"Long-term data on a Parkinson’s drug candidate will be presented in Seoul. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxQQ2V6bTBCRkdKdmlZSmRNRm9KXzRoY1QzRHFqNkVBODNyN3dOYmdENU1ZRU56R3JKV3RYRjlteDBhZzR3OFZLTktrZDY2VUg1M3JVdVp4MzZFcnBjZDJrTUgtLUIyUVNtVHhieHdKelZ6bTYtNjNQZmVhUG9GT3lQWEZGWWFzLWJqaXY4QnVyM2N2bnV4UjR2VVRTbUl3UFdOUk9ocnlaVU1CQnhXX09IcEswTldfaGNkRVo0?oc=5","Tue, 29 Sep 2026 21:50:00 GMT","Long-term data on a Parkinson’s drug candidate will be presented in Seoul. Stock Titan","Stock Titan",{"title":182,"link":183,"pubDate":184,"description":185,"source":186},"VSAT Stock Clocks Best Day In Over 10 Months — Analyst Calls It ‘Last Major Global Satellite Spectrum Play’ After Rocket Lab-Iridium Deal - Stocktwits","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiowJBVV95cUxNRjdKSFRuaFFnVmlzYjJqTU51Rmg2NERqNGROZXZYS1pTSjJOTy1HazNwZDBTYi1CRkFZNUY5cjBKMFMyWFJJQkM1T0Q5NzVzTURzdnNUdTNkdExLOHBuQWZSdHNOUEplZWVwOUV5NXdSdDF2Q1dJSVNOR1Z6OEJodG9HeDdYWGVURWI1RWk1di1SbWR3ZmJVQWRxanVTQ3VKUWNFYVdLSEtoSzJSNkVIcEhqcWMwMGZnSFA1UlNVTGdGellpdlJnNy1keGFrcTdYS1BNYmpjWlROb2FFUnhZOHVCN0VRUk5jMzhrNnlIWENOSGt5ZzE4QVBqV0o1aTBwdmI4QUw0QUI0V2FLSnd2aEdUR21mSTJRM3RXTnpCOGoxRFE?oc=5","Sun, 04 Oct 2026 05:31:04 GMT","VSAT Stock Clocks Best Day In Over 10 Months — Analyst Calls It ‘Last Major Global Satellite Spectrum Play’ After Rocket Lab-Iridium Deal Stocktwits","Stocktwits",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration - markets.businessinsider.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi2gJBVV95cUxQbnZnVWRBT0tUU1FxRGpzeno4WE5xRnZfa1pZck9NbGRyMF9RLUQzRF9SeHR6dXRHaVh4bEk3TTlSRElPZGdQTldEWmtfaHFVOUg0UmNlVEM4M0tnWVlzWW1yTWxYbHVOblpHR1JMMlAyVUpwa19SZXdueXk1X2kzU1dnMHV4cll5dEtDZDRHNHcxMUpDVXVDdVB1bU04elg1ZFRFaWw4UlhmaUhlY013RENjeE5TeEt1cTAwSTRpQnBqYlFwOUl1OG95b2lHeTJHbW9yWklKSV9aTVNMQ0RuTUhHbkVMT2hUcWdsZHcydnNpZjI2TkdhNWN3c3RfZmY2Vjktdmt2Q2tGNUNmRVVLM1VqS0thUUp5ZGRlbGdkZUo4R3NYTEJaSGQzdXVPLWlZOTd3UHF6V29YTmVLS1JMT0paek40U3JtMVJnZExfZkpES3d3Z3VfcFln?oc=5","Thu, 01 Oct 2026 14:35:30 GMT","Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration markets.businessinsi...","markets.businessinsider.com",{"title":194,"link":195,"pubDate":196,"description":197,"source":198},"Form 8K Gain Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiqwFBVV95cUxNbmptdlhScHdnZzZBQjlvNkV4M0tfZGhBbU1RTW5BWFlvTVctRHJsSFpvWHJhUjNpd2JGRy0tVV9rWWZjTllfN0c2VjhYNmpUS0VuU0lVVENnczM3V1ZjQ1hlODJORHd2UmN0MnBwM2Jqcnk4SXU4em1aQVhQbk9MRUVlbjU5Wm1jZUwtZjFndi0tZThvVTV5YVJJQmtGbHJBVlRIeWV5Sy1HT0U?oc=5","Mon, 28 Sep 2026 21:26:30 GMT","Form 8K Gain Therapeutics Inc For: 28 September By Investing.com Investing.com South Africa","Investing.com South Africa",{"title":200,"link":201,"pubDate":202,"description":203,"source":204},"Gain Therapeutics reports stable motor scores in Parkinson’s trial By Investing.com - Investing.com UK","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixAFBVV95cUxNRTF4RVNvSE9JWlF4cUQxZmlwT1ZaSGxxZ29GQlpoQlc5Z3k0azNXN2ptNjBpOGNPckVFMm1zNS1VeVNSaU5jc0kyNVJyVzJOM0xsUE05NmNYTHFmRVAtYkp5RjNWaW05dUo1TzdtN0x0dWQ2bFhSclhTMENPY2ZxcDAtNmFlZmlVZ1ZMY0ZNOFRsb3RQYU5ycDhiQklfTmhrNG1PbFc0M1pwMHZkOVhGUV83TGVtM3JrbHVSR1c3RWxzbGEt?oc=5","Thu, 01 Oct 2026 13:34:00 GMT","Gain Therapeutics reports stable motor scores in Parkinson’s trial By Investing.com Investing.com UK","Investing.com UK",{"title":206,"link":207,"pubDate":208,"description":209,"source":210},"Gain Therapeutics Names CEO as Interim CFO - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMimgFBVV95cUxObVh1dk04Wmdlc3Q2VTE4WG1ZV0w3Z3IyVmxKNjlSSldHenQ4QW9mNFl0TXhJd29PLTVLS0p1dnVlUVlhbmZja09CSUFUTE9LdTR1VjRsSEt6M0FoUW1jZHNCRk1pN0plNjVnb2NaZk14QTdHVkMxMmJaTEZPd2xMdW1NWGpPcjFNUEJlNkNYTlRBMzFFQlZfbjJB?oc=5","Mon, 28 Sep 2026 21:06:40 GMT","Gain Therapeutics Names CEO as Interim CFO TipRanks","TipRanks",{"title":212,"link":213,"pubDate":214,"description":215,"source":210},"Gain Therapeutics highlights promising Parkinson’s Phase 1b data - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMitgFBVV95cUxPX2FuZ2FVcUxISzdtc1FnTzNtSGNZR3lBa0lRb3pnMjlkcnJHQ2U2d0V0VWljMVZUNUYzcVVkekhLNTg3Z01kSTQ0TTlHeFdYd0tyUVFwclRKN0FYbFBMeUg4OUppNjRENk13ZWQtTTZsY1FUbUlPRkVPRWVIQXJ5a1ZHR0xoYVBGdmI1WXVzSTlieFBJU2VmNFZETFF0UDlsNHRQMk1pbjk3d1NQa0hEX1BjTVFnUQ?oc=5","Thu, 01 Oct 2026 14:00:22 GMT","Gain Therapeutics highlights promising Parkinson’s Phase 1b data TipRanks"]